title: Does eradication of Helicobacter pylori alone heal duodenal ulcers?
abstract: BACKGROUND
  Eradication of Helicobacter pylori infection prevents duodenal ulcer (DU) relapse, but it remains uncertain whether eradication of H. pylori alone heals duodenal ulceration.
  
  
  OBJECTIVE
  To test the hypothesis that eradication of H. pylori infection is accompanied by healing of duodenal ulcer.
  
  
  METHODS
  A total of 115 consecutive patients with endoscopically confirmed H. pylori-infected duodenal ulcer were randomly assigned to one of two groups. Group BTC patients received a 1-week course of colloidal bismuth subcitrate 220 mg b.d., tinidazole 500 mg b.d., clarithromycin 250 mg b.d. Group OBTC patients received omeprazole 20 mg daily for 4 weeks with the BTC regimen during the first week. Endoscopy with antral biopsies and 13C-urea breath test (UBT) were performed before and 4 weeks after completion of the 7-day triple or quadruple therapy.
  
  
  RESULTS
  Eight patients dropped out (four in BTC and four in OBTC). Duodenal ulcer healing rates on an intention-to-treat basis in BTC and OBTC were 86% (95% CI: 77-95%) and 90% (95% CI: 82-98%), respectively. The eradication rates of H. pylori on an intention-to-treat basis in BTC and OBTC were 88% (95% CI: 79-96%) and 91% (95% CI: 84-99%), respectively. There were no statistically significant differences in ulcer healing rates and eradication rates between these two groups (P > 0.05). Epigastric pain resolved more rapidly in patients assigned to OBTC compared with those assigned to BTC. Both of the two regimens were well tolerated with only minor side-effects (3% of the 115 patients) and the compliance was good.
  
  
  CONCLUSIONS
  BTC is a very effective H. pylori eradication regimen. Almost all duodenal ulcers heal spontaneously after cure of H. pylori infection using a 1-week low-dose bismuth-based triple therapy. Treating duodenal ulcer with simultaneous administration of omeprazole achieves ulcer pain relief more rapidly.
authors.affiliation: Shanghai Second Medical University Affiliated Ren-ji Hospital, Shanghai Institute of Digestive Disease, 145 Shan-dong Zhong Road, Shanghai 200001, People's Republic of China.
authors.forename: Z Z
authors.initials: ZZ
authors.lastname: Ge
authors.forename: D Z
authors.initials: DZ
authors.lastname: Zhang
authors.forename: S D
authors.initials: SD
authors.lastname: Xiao
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: Y B
authors.initials: YB
authors.lastname: Hu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000209:etiology* / Q000382:microbiology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use; D010146:Pain / Q000209:etiology; D011446:Prospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009853:Omeprazole